There is no doubt that Ginkgo Bioworks Holdings Inc. (DNA) ticks all the boxes.

Ginkgo Bioworks Holdings Inc. (NYSE: DNA) stock fell -0.60% on Friday to $1.66 against a previous-day closing price of $1.67. With 14.07 million shares changed hands, the volume of the stock remained lighter than its average volume of 23.98 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7200 whereas the lowest price it dropped to was $1.6500. The 52-week range on DNA shows that it touched its highest point at $6.38 and its lowest point at $1.45 during that stretch. It currently has a 1-year price target of $4.92.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNA was down-trending over the past week, with a drop of -9.78%, but this was down by -2.35% over a month. Three-month performance dropped to -31.97% while six-month performance fell -48.13%. The stock lost -67.06% in the past year, while it has lost -1.78% so far this year. A look at the trailing 12-month EPS for DNA yields -2.23 with Next year EPS estimates of -0.36. For the next quarter, that number is -0.21. This implies an EPS growth rate of -6.90% for this year and 74.10% for next year.

Float and Shares Shorts:

At present, 1.63 billion DNA shares are outstanding with a float of 573.64 million shares on hand for trading. On Oct 13, 2022, short shares totaled 156.3 million, which was 8.33% higher than short shares on Sep 14, 2022. In addition to Dr. Jason Kelly as the firm’s Founder, CEO & Director, Dr. Reshma P. Shetty serves as its Founder, Pres, COO & Director.

Institutional Ownership:

Through their ownership of 75.64% of DNA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.45% of DNA, in contrast to 36.34% held by mutual funds. Shares owned by individuals account for 25.72%. As the largest shareholder in DNA with 15.26% of the stake, Baillie Gifford & Co. holds 206,667,116 shares worth 206,667,116. A second-largest stockholder of DNA, ARK Investment Management LLC, holds 133,686,627 shares, controlling over 9.87% of the firm’s shares. Viking Global Investors LP is the third largest shareholder in DNA, holding 101,834,126 shares or 7.52% stake. With a 6.85% stake in DNA, the Scottish Mortgage Investment Trus is the largest stakeholder. A total of 92,830,293 shares are owned by the mutual fund manager. The ARK Innovation ETF, which owns about 6.74% of DNA stock, is the second-largest Mutual Fund holder. It holds 91,352,944 shares valued at 154.39 million. ARK Genomic Revolution ETF holds 3.20% of the stake in DNA, owning 43,312,439 shares worth 73.2 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNA since 9 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNA analysts setting a high price target of $12.00 and a low target of $2.00, the average target price over the next 12 months is $4.93. Based on these targets, DNA could surge 622.89% to reach the target high and rise by 20.48% to reach the target low. Reaching the average price target will result in a growth of 196.99% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DNA will report FY 2022 earnings on 03/26/2024. Analysts have provided yearly estimates in a range of -$0.14 being high and -$1.51 being low. For DNA, this leads to a yearly average estimate of -$1.23. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Ginkgo Bioworks Holdings Inc. surprised analysts by -$0.15 when it reported -$0.41 EPS against a consensus estimate of -$0.26. The surprise factor in the prior quarter was -$0.23. Based on analyst estimates, the high estimate for the next quarter is -$0.05 and the low estimate is -$0.42. The average estimate for the next quarter is thus -$0.21.

Summary of Insider Activity:

Insiders traded DNA stock several times over the past three months with 8 Buys and 131 Sells. In these transactions, 160,486 shares were bought while 21,362,052 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has risen to 173 over the past year. The total number of shares bought during that period was 30,726,991 while 317,867,363 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *